Silicon Valley Capital Partners Astrazeneca PLC Transaction History
Silicon Valley Capital Partners
- $766 Million
- Q1 2025
A detailed history of Silicon Valley Capital Partners transactions in Astrazeneca PLC stock. As of the latest transaction made, Silicon Valley Capital Partners holds 560 shares of AZN stock, worth $39,239. This represents 0.01% of its overall portfolio holdings.
Number of Shares
560
Previous 552
1.45%
Holding current value
$39,239
Previous $36,000
13.89%
% of portfolio
0.01%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding AZN
# of Institutions
1,428Shares Held
504MCall Options Held
10MPut Options Held
3.14M-
Price T Rowe Associates Inc Baltimore, MD57.1MShares$4 Billion0.52% of portfolio
-
Primecap Management CO Pasadena, CA40.7MShares$2.85 Billion2.53% of portfolio
-
Wellington Management Group LLP Boston, MA35.6MShares$2.5 Billion0.52% of portfolio
-
Bank Of America Corp Charlotte, NC31.8MShares$2.23 Billion0.19% of portfolio
-
Capital International Investors Los Angeles, CA31.3MShares$2.19 Billion0.47% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $217B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...